SummaryRMgm-655
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21899698 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA cl15cy1 |
Other information parent line | A reference wild type clone from the ANKA strain of P. berghei (PubMed: PMID: 17406255). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | E. Laurentino, C.J. Janse, A.P. Waters |
Name Group/Department | Leiden Malaria Research Group |
Name Institute | Leiden University Medical Center |
City | Leiden |
Country | The Netherlands |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-655 |
Principal name | 1054cl1 |
Alternative name | fact-l::c-myc |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | All blood stages express c-myc::FACT-L as shown by IFA (and Western analysis). Signals are mainly observed in the nuclei of parasites. |
Gametocyte/Gamete | Male and female gametocytes express c-myc::FACT-L as shown by IFA. Signals are mainly observed in the nuclei of parasites with strong levels signals in the nuclei of male gametocytes. |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation BLAST-based homology searches with PBANKA_123220 identified clear homology to the eukaryotic SPT16 protein (e.g. 30% identity, 41% similarity to SPT16 of Saccharomyces cerevisiae) with an identical arrangement of the Rttp106-like, SPT16 and M24 peptidase domains Attempts to disrupt the fact-l gene in P. berghei were unsuccessful (see RMgm-255), indicating an essential role of FACT-L for blood stage development/multiplication Phenotype analyses of the mutant expressing c-myc-tagged FACT-L by IFA and Western analyses indicate that FACT-L is is located predominantly in the parasite nucleus with evidence that a small proportion of FACT-L is located in the cytoplasm. Expression was detected in all blood stages with high levels of FACT-L in the nuclei of male gametocytes. Additional information Phenotype analyses of the promoter-swap mutant indicate that FACT-L plays an important role in the production of fertile male gametes. The promoter-swap mutant produced normal numbers of female and male gametocytes. Fertility of female gametes is comparable to wild type female gametes as shown by crossing with wild type male gametes. Male gametocytes showed delayed DNA replication and gamete formation. Male gamete fertility is strongly reduced, resulting in strongly reduced ookinete formation. Residual ookinetes generated oocysts that arrested early in development and failed to enter sporogony. Other mutants
|
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1232200 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0517400 | ||||||||||||||||||||||||||
Gene product | FACT complex subunit SPT16, putative | ||||||||||||||||||||||||||
Gene product: Alternative name | FACT-L; FACT | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | c-myc | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | Plasmid single cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | For C-terminal tagging of FACT-L with a c-Myc tag, we used the standard vector pL1080 (http://www.mr4.org) as a backbone. This vector contains a double c-Myc tag. A 1.4 kb fragment of the C-terminus of fact-l was PCR-amplified using the primer pair 2779/3171 (CTGATgaattcATGCATGATGAAAT (F); TAggatccATTTTTTTTCCTCTTTC (R)), subcloned into TOPO vector (Invitrogen) and subsequently transferred into SacII/BamHI-digested pL1080, resulting in vector pL1289. After linearization with XbaI this construct was transfected into P. berghei (ANKA) parasites of reference line cl15cy1. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |